Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteoporosis: trials and tribulations

E Seeman1

  • 1Department of Endocrinology, Austin & Repatriation Medical Centre, University of Malbourne, Australia.

The American Journal of Medicine
|August 18, 1997
PubMed
Summary

Detecting a worthwhile 30-50% reduction in fracture risk requires large, long-term studies. Hormone replacement therapy and bisphosphonates show promise for reducing vertebral and hip fractures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Provision of High Protein Foods Slows the Age-Related Decline in Nutritional Status in Aged Care Residents: A Cluster-Randomised Controlled Trial.

The journal of nutrition, health & aging·2023
Same author

Effect of dietary sources of calcium and protein on hip fractures and falls in older adults in residential care: cluster randomised controlled trial.

BMJ (Clinical research ed.)·2021
Same author

Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Systemic mastocytosis identified in two women developing fragility fractures during lactation.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Bone remodeling markers: so easy to measure, so difficult to interpret.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015

Area of Science:

  • Osteoporosis research
  • Clinical trial design
  • Pharmacological interventions

Background:

  • A 30-50% reduction in fracture risk is considered a clinically significant benefit.
  • Detecting this benefit is challenging due to low annual fracture event rates in at-risk populations.
  • Understanding these rates is crucial for patient education, trial power, and assessing treatment necessity and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of various treatments for reducing fracture risk.
  • To highlight the challenges in clinical trial design for osteoporosis treatments.
  • To identify the most promising current therapeutic options for osteoporosis.

Main Methods:

  • Review of existing clinical trial data and study designs for osteoporosis treatments.
  • Focus on studies with large patient samples, long durations (3-4 years), blinding, and intention-to-treat analyses.
  • Assessment of evidence for hormone replacement therapy, bisphosphonates, and other agents.

Main Results:

  • Hormone replacement therapy (HRT) demonstrates a ~40% reduction in vertebral fracture risk and potential hip fracture risk reduction.
  • Bisphosphonates, particularly alendronate, show credible evidence for ~40-50% reduction in vertebral and hip fracture risk.
  • Evidence for other agents like etidronate, calcitonin, vitamin D, and calcium is less certain or limited to specific populations.

Conclusions:

  • Uncertainty in osteoporosis treatment efficacy and safety may stem from study design and execution issues.
  • Hormone replacement therapy and bisphosphonates, especially alendronate, are currently the most promising options for reducing fracture risk.
  • Further research is needed, particularly for men and corticosteroid-induced osteoporosis.

Related Experiment Videos